Америкалық онколог дәрігері Николас Дж. Вогельзангтың ғылыми еңбектері

American physician

Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

Vogelzang joined Comprehensive Cancer Centers of Nevada in 2009 as a medical oncologist and serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. Since 2004, he has been Head of the Genitourinary Oncology and Clinical Professor of Medicine for the University of Nevada School of Medicine in Las Vegas and Reno, Nevada. He served as Director, Executive Vice President for Academic Affairs and Professor at Nevada Cancer Institute (NVCI) from 2004 to 2009. During his tenure at the University of Chicago, he served as Professor of Medicine and Surgery (Urology) (1993 to 2003), Director for the University of Chicago Cancer Research Center (1999–2003), and was named the first Fred C. Buffett Professor in Medicine and chair in Genitourinary Oncology (1999–2003). Vogelzang received his M. D. from the University of Illinois at Chicago in 1974. He completed his internship, residency and chief residency in internal medicine at Rush Presbyterian St. Luke's Medical Center in Chicago, followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. Vogelzang became the first editor of the Textbook of Genitourinary Oncology and remains the lead editor today.

In 2002, Vogelzang directed the largest Phase II trial for mesothelioma using pemetrexed (brand name Alimta, by Eli Lilly). Pemetrexed is an antifolate, a class of drugs that targets the folic acid metabolic pathway. The results of the trial showed tumors shrank in 41 percent of patients on pemetrexed in combination with a more commonly used chemotherapy agent called cisplatin. Only 17 percent of patients receiving cisplatin alone experienced tumor shrinkage. Additionally, those on the pemetrexed combination lived nearly three months longer than those on cisplatin alone.

Vogelzang is a corporate consultant for the following companies: Aveo Pharmaceuticals Inc., Celgene Corporation, Dendreon, Exelixis Inc., Novartis AG, OncoGeneX/Teva Pharmaceutical Industries Ltd., Veridex, and Viamet. He is also a member of the speakers' bureaus for Caris Life Sciences, Dendreon, Eli Lilly and Company, Inc., Novartis AG, and Sanofi Aventis U. S.

Study May Alter Approach to Prostate Cancer The New York Times, June 1, 2014. Top Docs 2014 Dr. Nicholas Vogelzang Vegas Seven, May 29, 2014. Is There A Link Between Prostate Cancer and Chronic Inflammation? Forbes, April 21, 2014. The Doctor Will "Like" You Now Desert Companion, August 2013. Antiangiogenic Agents, Chemotherapy, and the Treatment of Metastatic Transitional Cell Carcinoma Journal of Clinical Oncology, January 22, 2013. A Man of Many Battles: Genitourinary Expert Spurs Advances Amid Challenges onclive. com, November 12, 2012. Enzalutamide — A Major Advance in the Treatment of Metastatic Prostate Cancer The New England Journal of Medicine, September 27, 2012. Another chance for Las Vegas man to fight off cancer Las Vegas Review Journal, July 16, 2012. Event seeks to raise awareness for prostate cancer Las Vegas Review Journal, September 22, 2011. Clinical trials give cancer patients hope, time Las Vegas Review Journal, January 29, 2011. Nicholas J. Vogelzang, MD, Receives Award From the Kidney Cancer Association. Medscape Today: Oncologists in the News, October 6, 2010. With Dr. Nicholas Vogelzang KSNV Ch.3, July 26, 2010. Patients from several states seek cancer treatment Las Vegas Review Journal July 20, 2010. Cancer patients find new hope, FDA approves new but costly treatment for prostate cancer. Las Vegas Review Journal July 16, 2010. Study: Cancer Patients at Higher Suicide Risk. Time Magazine, February 3, 2010